 |
449 Diseases |  |
58 Trials |
|
58 Trials |  |
3605 News |  |
| «12...1314151617181920212223...2425» |
- | Leukine (sargramostim) / Partner Therap, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
PD(L)-1 Biomarker: A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma (clinicaltrials.gov) - Sep 18, 2015
P2/3, N=400, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting
- | Leukine (sargramostim) / Partner Therap, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
PD(L)-1 Biomarker: A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma (clinicaltrials.gov) - Sep 16, 2015
P2/3, N=400, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Initiation date: Mar 2015 --> Oct 2015
- Trial withdrawal: Autologous Stem Cell Transplants for Chronic Myelogenous Leukemia (clinicaltrials.gov) - Aug 25, 2015
P2, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Initiation date: Mar 2015 --> Oct 2015 Terminated --> Withdrawn
- Leukine (sargramostim) / Partner Therap
Trial primary completion date: Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant (clinicaltrials.gov) - Aug 24, 2015
P2, N=10, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Terminated --> Withdrawn Trial primary completion date: Jul 2015 --> Jul 2017
- Leukine (sargramostim) / Partner Therap
Trial primary completion date, Surgery, Metastases: SWOG-E4697: Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery (clinicaltrials.gov) - Aug 21, 2015
P3, N=815, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2015 --> Jul 2017 Trial primary completion date: Jan 2013 --> Oct 2012
- ||||||| Leukine (sargramostim) / Partner Therap, ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Trial completion, Phase classification, Trial primary completion date, Combination therapy: High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML) (clinicaltrials.gov) - Aug 20, 2015
P3, N=94, Completed, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jan 2013 --> Oct 2012 Active, not recruiting --> Completed | Phase classification: PN/A --> P3 | Trial primary completion date: Nov 2016 --> Aug 2015
- ||||||| Leukine (sargramostim) / Partner Therap, IMA-901 / Immatics, sunitinib / Generic mfg.
Trial completion, IO biomarker, Metastases: IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma (clinicaltrials.gov) - Aug 19, 2015
P3, N=330, Completed, Sponsor: immatics Biotechnologies GmbH
Active, not recruiting --> Completed | Phase classification: PN/A --> P3 | Trial primary completion date: Nov 2016 --> Aug 2015 Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap
Trial primary completion date: Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma (clinicaltrials.gov) - Aug 14, 2015
P2, N=340, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Dec 2015 --> Dec 2016
- Zeltherva (galinpepimut-S) / SELLAS Life Sciences
Trial primary completion date: WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Aug 13, 2015
P2, N=29, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- Leukine (sargramostim) / Partner Therap
Trial primary completion date: CO98601: Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma (clinicaltrials.gov) - Aug 13, 2015
P1, N=18, Completed, Sponsor: University of Wisconsin, Madison
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Nov 2006 --> Mar 2001
- Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Combination therapy: Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma (clinicaltrials.gov) - Aug 13, 2015
P2, N=39, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Nov 2006 --> Mar 2001 Initiation date: Jun 2015 --> Dec 2015
- | Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Enrollment closed: Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma (clinicaltrials.gov) - Aug 13, 2015
P3, N=1660, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Jun 2015 --> Dec 2015 Recruiting --> Active, not recruiting
- ||||| Leukine (sargramostim) / Partner Therap
New P2 trial: Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia (clinicaltrials.gov) - Aug 11, 2015
P2, N=165, Not yet recruiting, Sponsor: Sanofi
- | Leukine (sargramostim) / Partner Therap
Trial completion: CO98601: Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma (clinicaltrials.gov) - Aug 9, 2015
P1, N=18, Completed, Sponsor: University of Wisconsin, Madison
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap
Enrollment change, Metastases: Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung (clinicaltrials.gov) - Jul 13, 2015
P1, N=40, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed N=85 --> 40
- Leukine (sargramostim) / Partner Therap
Trial completion, Metastases: Sargramostim in Treating Patients With Kidney Cancer That Has Spread to the Lung (clinicaltrials.gov) - Jul 9, 2015
P2, N=27, Completed, Sponsor: Alliance for Clinical Trials in Oncology
N=85 --> 40 Active, not recruiting --> Completed
- || Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Roche
Trial primary completion date: Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma (clinicaltrials.gov) - Jul 6, 2015
P2, N=52, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Trial primary completion date: May 2016 --> May 2017
- Leukine (sargramostim) / Partner Therap, Reolysin (pelareorep) / Oncolytics, Andrus Reo
Enrollment open, Combination therapy: Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors (clinicaltrials.gov) - Jun 30, 2015
P1, N=21, Recruiting, Sponsor: Mayo Clinic
Trial primary completion date: May 2016 --> May 2017 Not yet recruiting --> Recruiting
- ProstVac (rilimogene galvacirepvec) / Bavarian Nordic
Trial completion: A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer (clinicaltrials.gov) - Jun 30, 2015
P2, N=50, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
New P2 trial, Combination therapy: Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma (clinicaltrials.gov) - Jun 29, 2015
P2, N=39, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | Leukine (sargramostim) / Partner Therap, SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
Enrollment open: NCI-2015-00694: SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Jun 27, 2015
P2, N=50, Recruiting, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Leukine (sargramostim) / Partner Therap
Trial primary completion date: Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer (clinicaltrials.gov) - Jun 25, 2015
P=N/A, N=45, Active, not recruiting, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting Trial primary completion date: May 2015 --> May 2016
- ||||||| zosuquidar (LY335979) / Kanisa Pharma
Trial completion: Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia (clinicaltrials.gov) - Jun 24, 2015
P3, N=449, Completed, Sponsor: Eastern Cooperative Oncology Group
Trial primary completion date: May 2015 --> May 2016 Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap
Trial initiation date, IO biomarker: The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer (clinicaltrials.gov) - Jun 18, 2015
P1, N=20, Not yet recruiting, Sponsor: University of Colorado, Denver
Active, not recruiting --> Completed Initiation date: Mar 2015 --> Dec 2015
- Leukine (sargramostim) / Partner Therap
Enrollment change, Combination therapy, Metastases: Randomized Phase 2 Trial of Pre-chemotherapy Leukine vs. Leukine-Dexamethasone in Combination With Gemzar & 5-FU in Patients With Metastatic Renal Cell Carcinoma (clinicaltrials.gov) - Jun 18, 2015
P2, N=0, Withdrawn, Sponsor: University of Kentucky
Initiation date: Mar 2015 --> Dec 2015 N=64 --> 0
- | Leukine (sargramostim) / Partner Therap
New P1 trial: Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent (clinicaltrials.gov) - Jun 12, 2015
P1, N=20, Recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
- Leukine (sargramostim) / Partner Therap, SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
Trial initiation date: SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy (clinicaltrials.gov) - Jun 11, 2015
P1, N=18, Not yet recruiting, Sponsor: Roswell Park Cancer Institute
N=64 --> 0 Initiation date: Feb 2015 --> Jun 2015
- | Leukine (sargramostim) / Partner Therap, SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
New P2 trial: NCI-2015-00694: SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - May 28, 2015
P2, N=50, Not yet recruiting, Sponsor: Roswell Park Cancer Institute
- | Leukine (sargramostim) / Partner Therap
New P4 trial, Immune cell: Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma (clinicaltrials.gov) - May 22, 2015
P4, N=20, Recruiting, Sponsor: Mayo Clinic
- Leukine (sargramostim) / Partner Therap
Trial completion, Enrollment change: Sargramostim for Myeloid Dendritic Cell Deficiency (clinicaltrials.gov) - May 21, 2015
P1, N=2, Completed, Sponsor: Johns Hopkins University
Initiation date: Feb 2015 --> Jun 2015 Recruiting --> Completed | N=15 --> 2
- | Leukine (sargramostim) / Partner Therap, Reolysin (pelareorep) / Oncolytics, Andrus Reo
New P1 trial, Combination therapy: Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors (clinicaltrials.gov) - May 14, 2015
P1, N=21, Not yet recruiting, Sponsor: Mayo Clinic
- Leukine (sargramostim) / Partner Therap
Enrollment change: Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer (clinicaltrials.gov) - May 5, 2015
P1/2, N=0, Withdrawn, Sponsor: Roger Williams Medical Center
Recruiting --> Completed | N=15 --> 2 N=60 --> 0
- Promune (agatolimod) / Pfizer, Leukine (sargramostim) / Partner Therap
Phase classification, Surgery, Metastases: Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery (clinicaltrials.gov) - Apr 30, 2015
P1, N=22, Completed, Sponsor: Ahmad Tarhini
N=60 --> 0 Phase classification: P=N/A --> P1
- Leukine (sargramostim) / Partner Therap
Enrollment closed, Enrollment change: Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer (clinicaltrials.gov) - Apr 27, 2015
P1, N=7, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Phase classification: P=N/A --> P1 Suspended --> Active, not recruiting | N=12 --> 7
- | Leukine (sargramostim) / Partner Therap
Trial completion: Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer (clinicaltrials.gov) - Apr 27, 2015
P2, N=0, Completed, Sponsor: National Cancer Institute (NCI)
Suspended --> Active, not recruiting | N=12 --> 7 Active, not recruiting --> Completed
- Intron A (interferon ?-2b) / Merck (MSD), Biogen, Leukine (sargramostim) / Partner Therap
Trial completion, Combination therapy, Metastases: Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA) (clinicaltrials.gov) - Apr 20, 2015
P1, N=33, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap
Trial completion date, Trial termination: GM-CSF in Patients With Pulmonary Alveolar Proteinosis (clinicaltrials.gov) - Apr 19, 2015
P2, N=48, Terminated, Sponsor: The Cleveland Clinic
Active, not recruiting --> Completed Trial completion date: Sep 2004 --> Dec 2005 | Recruiting --> Terminated
- ||||| NeuVax (nelipepimut-S) / Dr. Reddy's
Enrollment closed, Trial primary completion date: PRESENT: Efficacy and Safety Study of NeuVax (clinicaltrials.gov) - Apr 15, 2015
P3, N=700, Active, not recruiting, Sponsor: Galena Biopharma, Inc.
Trial completion date: Sep 2004 --> Dec 2005 | Recruiting --> Terminated Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Apr 2018
- Leukine (sargramostim) / Partner Therap
Trial completion, Surgery: Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma (clinicaltrials.gov) - Apr 15, 2015
P2, N=40, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Apr 2018 Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap
Trial primary completion date: Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer (clinicaltrials.gov) - Apr 14, 2015
P=N/A, N=45, Active, not recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Trial primary completion date: May 2014 --> May 2015
- Leukine (sargramostim) / Partner Therap
Trial primary completion date, Metastases: Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma (clinicaltrials.gov) - Apr 14, 2015
P=N/A, N=23, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: May 2014 --> May 2015 Trial primary completion date: Sep 2014 --> Sep 2015
- Rituxan (rituximab) / Roche, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Trial primary completion date: Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma (clinicaltrials.gov) - Apr 14, 2015
P1, N=42, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Sep 2014 --> Sep 2015 Trial primary completion date: Sep 2014 --> Sep 2015
- |||| Leukine (sargramostim) / Partner Therap
Trial primary completion date, Biopsy: Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma (clinicaltrials.gov) - Apr 14, 2015
P3, N=380, Recruiting, Sponsor: Jonsson Comprehensive Cancer Center
Trial primary completion date: Sep 2014 --> Sep 2015 Trial primary completion date: Mar 2015 --> Mar 2016
- AST-301 / University of Washington, Aston Sci., EpiThany
Trial primary completion date: Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer (clinicaltrials.gov) - Apr 14, 2015
P2, N=38, Active, not recruiting, Sponsor: University of Washington
Trial primary completion date: Mar 2015 --> Mar 2016 Trial primary completion date: Feb 2015 --> Jul 2015
- Leukine (sargramostim) / Partner Therap, Herceptin (trastuzumab) / Roche
Trial primary completion date: Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer (clinicaltrials.gov) - Apr 14, 2015
P2, N=26, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Trial primary completion date: Feb 2015 --> Jul 2015 Trial primary completion date: Dec 2014 --> Dec 2018
- || Leukine (sargramostim) / Partner Therap, ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Trial primary completion date, Combination therapy: High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML) (clinicaltrials.gov) - Apr 14, 2015
P=N/A, N=98, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2014 --> Dec 2018 Trial primary completion date: Nov 2015 --> Nov 2016
- Leukine (sargramostim) / Partner Therap, Herceptin (trastuzumab) / Roche
Phase classification: Biological Therapy in Treating Women With Stage IV Breast Cancer (clinicaltrials.gov) - Mar 31, 2015
P1, N=6, Completed, Sponsor: Barbara Ann Karmanos Cancer Institute
Trial primary completion date: Nov 2015 --> Nov 2016 Phase classification: P1/2 --> P1
- | Leukine (sargramostim) / Partner Therap
Trial completion: COG-AOST0221: Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma (clinicaltrials.gov) - Mar 31, 2015
P2, N=49, Completed, Sponsor: Children's Oncology Group
Phase classification: P1/2 --> P1 Active, not recruiting --> Completed
- Leukine (sargramostim) / Partner Therap, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Trial termination, IO biomarker, Metastases: Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors (clinicaltrials.gov) - Mar 25, 2015
P1, N=2, Terminated, Sponsor: Roger Williams Medical Center
Active, not recruiting --> Completed N=16 --> 2 | Recruiting --> Terminated; Funding ended
- Leukine (sargramostim) / Partner Therap, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Trial termination, Trial primary completion date, IO biomarker, Metastases: Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - Mar 25, 2015
P1, N=5, Terminated, Sponsor: Roger Williams Medical Center
N=16 --> 2 | Recruiting --> Terminated; Funding ended N=24 --> 5 | Recruiting --> Terminated | Trial primary completion date: May 2015 --> Dec 2014; Funding ended